The U.S. Levodopa market saw a sharp price fall in April xxxx, prolonging the downward trend from the first quarter of the year.
Prices of Levodopa hit bottoms by late April at USD xx,xxx per metric ton CFR Los Angeles as weakening demand fundamentals, defensive buying, and strengthening global trade pressures took their toll.
The steady drop in Levodopa prices has been significantly affected by conservative purchasing activity on the part of domestic consumers and high levels of inventories throughout the pharmaceutical industry. Market players have indicated that several buyers are avoiding bulk purchases and keeping their levels of exposure minimal in hopes of further price falls. The risk-averse mood has been supported by weaker downstream demand from pharmaceutical firms, which are running at lower capacity with weakening consumption and deteriorating new orders.
Adding to the bearish...
